Online healthcare companies are increasingly marketing GLP-1 prescriptions to people who aren't overweight or obese, according to a recent Bloomberg story. Federal regulators are starting to crack down on telehealth platforms for their compounded GLP-1 ads. So far, the FDA and FTC have targeted companies claiming their copycat weight loss drugs are the same as brand-name versions and that allegedly mislead consumers with misrepresented products and reviews. These actions could signal that the feds will next go after entities that advertise GLP-1s for unapproved uses, such as for cosmetic purposes for people whose BMI isn’t at least 27.

The news: Noom is now selling microdoses of compounded GLP-1 semaglutide for weight loss with a lower price tag and fewer side effects. Our take: GLP-1 microdosing is booming on social media trend and although weight loss drugmakers Novo and Lilly have neither studied nor endorsed mini doses, it’s another tactic for telehealth providers like Noom to stay in the weight loss game. We expect GLP-1 microdosing to gain marketing steam among telehealths this year.

Social media fuels micro-dosing trend with Ozempic: The trend speaks to the power of social health influencers, but emphasizes responsibility to marketers who need to make sure consumers are getting the most accurate drug information on the channel.